Mesoblast Limited (NASDAQ: MESO) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating.
ISCT Hails Landmark US FDA Approval of RYONCIL as Major Milestone for MSC Field [Yahoo! Finance]
Mesoblast Limited (NASDAQ: MESO) had its price target raised by analysts at Piper Sandler from $11.00 to $15.00. They now have an "overweight" rating on the stock.
Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease [Yahoo! Finance]
How has the FDA approval of Ryoncil affected Mesoblast's stock price? [Yahoo! Finance]